The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper versions. After an outcry, it’s reconsidering.

The government has suggested weight-loss drugs could boost the economy by helping obese people in England get back to work. But NHS experts have warned treatment services are already overstretched trying to deal with unprecedented demand from patients wanting these drugs.

Weight loss drugs are set to become cheaper and more accessible, a public health specialist says. The British government has announced a five-year trial of Mounjaro, which is ordinarily prescribed to treat diabetes, to see if it can help unemployed people who are obese get back to work.

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year trial investigating whether the use of the weight-loss drug tirzepatide helps get people back into employment.

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.